Literature DB >> 19223058

Covalent labeling of nuclear vitamin D receptor with affinity labeling reagents containing a cross-linking probe at three different positions of the parent ligand: structural and biochemical implications.

Taner Kaya1, Narasimha Swamy, Kelly S Persons, Swapna Ray, Scott C Mohr, Rahul Ray.   

Abstract

Structure-functional characterization of vitamin D receptor (VDR) requires identification of structurally distinct areas of VDR-ligand-binding domain (VDR-LBD) important for biological properties of 1alpha,25-dihydroxyvitamin D(3) (1,25(OH)(2)D(3)). We hypothesized that covalent attachment of the ligand into VDR-LBD might alter 'surface structure' of that area influencing biological activity of the ligand. We compared anti-proliferative activity of three affinity alkylating derivatives of 1,25(OH)(2)D(3) containing an alkylating probe at 1,3 and 11 positions. These compounds possessed high-affinity binding for VDR; and affinity labeled VDR-LBD. But, only the analog with probe at 3-position significantly altered growth in keratinocytes, compared with 1,25(OH)(2)D(3). Molecular models of these analogs, docked inside VDR-LBD tentatively identified Ser237 (helix-3: 1,25(OH)(2)D(3)-1-BE), Cys288 (beta-hairpin region: 1,25(OH)(2)D(3)-3-BE,) and Tyr295 (helix-6: 1,25(OH)(2)D(3)-11-BE,) as amino acids that are potentially modified by these reagents. Therefore, we conclude that the beta-hairpin region (modified by 1,25(OH)(2)D(3)-3-BE) is most important for growth inhibition by 1,25(OH)(2)D(3), while helices 3 and 6 are less important for such activity.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19223058      PMCID: PMC2696187          DOI: 10.1016/j.bioorg.2009.01.001

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  34 in total

1.  Probing the vitamin D sterol-binding pocket of human vitamin D-binding protein with bromoacetate affinity labeling reagents containing the affinity probe at C-3, C-6, C-11, and C-19 positions of parent vitamin D sterols.

Authors:  N Swamy; J Addo; M R Vskokovic; R Ray
Journal:  Arch Biochem Biophys       Date:  2000-01-15       Impact factor: 4.013

2.  Molecular modeling, affinity labeling, and site-directed mutagenesis define the key points of interaction between the ligand-binding domain of the vitamin D nuclear receptor and 1 alpha,25-dihydroxyvitamin D3.

Authors:  N Swamy; W Xu; N Paz; J C Hsieh; M R Haussler; G J Maalouf; S C Mohr; R Ray
Journal:  Biochemistry       Date:  2000-10-10       Impact factor: 3.162

3.  Critical role of helix 12 of the vitamin D(3) receptor for the partial agonism of carboxylic ester antagonists.

Authors:  Sami Väisänen; Mikael Peräkylä; Jouni I Kärkkäinen; Andreas Steinmeyer; Carsten Carlberg
Journal:  J Mol Biol       Date:  2002-01-11       Impact factor: 5.469

Review 4.  Vitamin D analogs as therapeutic agents: a clinical study update.

Authors:  J Ruth Wu-Wong; Jin Tian; David Goltzman
Journal:  Curr Opin Investig Drugs       Date:  2004-03

Review 5.  Vitamin D receptor agonists in the treatment of autoimmune diseases: selective targeting of myeloid but not plasmacytoid dendritic cells.

Authors:  Giuseppe Penna; Susana Amuchastegui; Gilles Laverny; Luciano Adorini
Journal:  J Bone Miner Res       Date:  2007-12       Impact factor: 6.741

6.  Crystal structures of the vitamin D nuclear receptor liganded with the vitamin D side chain analogues calcipotriol and seocalcitol, receptor agonists of clinical importance. Insights into a structural basis for the switching of calcipotriol to a receptor antagonist by further side chain modification.

Authors:  Giuseppe Tocchini-Valentini; Natacha Rochel; Jean-Marie Wurtz; Dino Moras
Journal:  J Med Chem       Date:  2004-04-08       Impact factor: 7.446

7.  1alpha,25-Dihydroxyvitamin D3-3beta-(2)-bromoacetate, an affinity labeling derivative of 1alpha,25-dihydroxyvitamin D3 displays strong antiproliferative and cytotoxic behavior in prostate cancer cells.

Authors:  Narasimha Swamy; Kelly S Persons; Tai C Chen; Rahul Ray
Journal:  J Cell Biochem       Date:  2003-08-01       Impact factor: 4.429

Review 8.  Vitamin D: more than a "bone-a-fide" hormone.

Authors:  Amelia L M Sutton; Paul N MacDonald
Journal:  Mol Endocrinol       Date:  2003-03-13

9.  A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer.

Authors:  T R J Evans; K W Colston; F J Lofts; D Cunningham; D A Anthoney; H Gogas; J S de Bono; K J Hamberg; T Skov; J L Mansi
Journal:  Br J Cancer       Date:  2002-03-04       Impact factor: 7.640

10.  A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma.

Authors:  K Dalhoff; J Dancey; L Astrup; T Skovsgaard; K J Hamberg; F J Lofts; O Rosmorduc; S Erlinger; J Bach Hansen; W P Steward; T Skov; F Burcharth; T R J Evans
Journal:  Br J Cancer       Date:  2003-07-21       Impact factor: 7.640

View more
  2 in total

1.  1α,25-Dihydroxyvitamin D3-3β-bromoacetate, a potential cancer therapeutic agent: synthesis and molecular mechanism of action.

Authors:  Rahul Ray; James R Lambert
Journal:  Bioorg Med Chem Lett       Date:  2011-02-18       Impact factor: 2.823

2.  Structural and molecular analyses of functional epitopes and escape mutants in Japanese encephalitis virus envelope protein domain III.

Authors:  Urmi Roy
Journal:  Immunol Res       Date:  2020-04       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.